Merck & Co. Inc. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant's portfolio of chronic obstructive pulmonary disease treatments with Verona Pharma's ...

Merck has reached an agreement to acquire British pharmaceutical company Verona Pharma in a deal worth around $10 billion, ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Merck & Co. has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive pulmonary disease treatment Ohtuvayre as it braces for the 2028 loss of ...

Source Reference: Nerli TF, et al "Brief outpatient rehabilitation program for post–COVID-19 condition: A randomized clinical trial" JAMA Netw Open 2024; DOI: 10.1001/jamanetworkopen.2024.50744.

The concept of SbD is critical in drug development and deployment, particularly concerning the exposure to metabolites and degradation products. This includes waste-safe management, good production ...

The new vaccine committee appointed by Secretary Robert F. Kennedy Jr. took minimal action in its first meeting.

The Business Research Company's The Specific Antiviral Drugs For COVID 19 Market Forecast To 2034 – For Business Leaders, Analysts, And Strategic Teams It will grow to $28.43 billion in 2029 at a ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

Only use certain shots free of an ingredient antivaccine groups have falsely tied to autism, the advisers said.